SEC Form 4 · accession 0001062993-16-012532
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Thomas Wegman
Officer — President · Director · 10% Owner
Period of report
Nov 28, 2016
Accepted (ET)
Nov 29, 2016 · 5:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.001 par valueF1 | Nov 28, 2016 | S | 11,055 | $48.0369 | D | 964,824 | D | |
| Common Stock, $.001 par valueF2 | Nov 29, 2016 | S | 8,945 | $48.3161 | D | 955,879 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $48.0369 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $47.50 to $49.40. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2The selling price of $48.3161 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $48.25 to $48.77. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.